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Abstract
Fallopian tube (FT) and endometrial urocortin 1 (Ucn1) and CRH-receptor (CRH-R1/CRH-R2)
expression were examined using quantitative-RT-PCR and immunohistochemistry in non-
pregnant and pregnant women (intrauterine, IUP; ectopic pregnancy, EP). Tubal Ucn1 mRNA
expression was higher in luteal compared to follicular phase (P<0.01) and equivalent to follicular
phase in FT from EP. Tubal CRH-R1/CRH-R2 mRNA was lower in luteal phase (P<0.05) and in
FT from EP compared to follicular phase (P<0.01). Ucn1 mRNA was lower in endometrium from
EP compared to IUP (P<0.05). CRH-R1 mRNA was higher in endometrium from EP compared to
viable IUP (P<0.05). No differences were observed in CRH-R2 expression. CRH-R1 protein was
primarily localised to epithelium of FT and endometrium. Quantitative analysis of tubal CRH-R1
protein expression reflected that seen at the mRNA level but endometrial expression was
equivocal. The demonstration of attenuated tubal/endometrial Ucn1/CRH-R expression in EP
further supports a role of the CRH-family in embryo implantation.
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Introduction
Tubal ectopic pregnancy remains a common cause of morbidity and occasional mortality
[1]. In the UK, between 2003 and 2005, early pregnancy bleeding was the third commonest
cause of maternal death and over 60% of these cases were due to ruptured tubal ectopic
pregnancies [2]. In the USA, ruptured tubal ectopic pregnancy remains the commonest cause
of pregnancy-related first trimester death [3]. In the developing world, the incidence of
ectopic pregnancy is much higher and one in ten women admitted with a diagnosis of
ectopic pregnancy ultimately die from the condition [4]. Despite advances in our
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understanding of intrauterine implantation and early pregnancy, our knowledge of the
complex molecular and cellular interactions that contribute to tubal implantation is limited
[5].
The corticotrophin releasing hormone (CRH) family includes a variety of neuropeptides,
including urocortin 1 (Ucn1), and the CRH receptors (types 1 and 2) (CRH-R1 and CRH-
R2) [6]. Ucn1, a 40 amino acid peptide, is closely related to CRH [7], not only in sequence
homology but also because it binds both CRH receptors with high affinity [8,9]. Ucn1 is
known to play a significant role in the physiology of human reproduction, including
steroidogenesis, myometrial contractility and the initiation of labour [6,10,11]. Ucn1 and the
CRH receptors are also thought to play an important part in endometrial decidualization and
successful intrauterine implantation [6,10]. Ucn1 is expressed in the endometrial epithelial
and stromal cells throughout the menstrual cycle [12], with the highest expression observed
in the secretory phase [13]. It induces endometrial cell decidualization even in the absence
of sex steroid hormones, and is also secreted by the stroma during decidualization
modulating the maternal response to the invading trophoblast [13].
Ucn1 is highly expressed by human extravillous trophoblast cells (EVT) (the invasive part
of the placenta) [14] and it has been reported to have a potent vasodilator action on the
placental bed [15]. Furthermore, higher Ucn1 levels have been observed in endometrial
flushings from women who achieved pregnancy after intrauterine insemination compared to
those who did not, suggesting that Ucn1 may only be secreted in appreciable amounts by a
receptive endometrium [16]. Both CRH-R1 and CRH-R2 [17,18] are also expressed in the
human endometrium throughout the menstrual cycle but only CRH-R1 is expressed on EVT
cells [19]. CRH-R2 is extensively expressed in vascular tissues [20,21], and its action on
vascular tone control promotes vasodilation [22,23]. Recent studies have shown that, in the
human endometrium, CRH-R1 antagonists have the potential to be used as abortive agents
(blockage of CRH-R1 in rats decreases implantation in rats in a dose-dependent way)
[19,24]. It has been also suggested that CRH-R1 takes part in the control of trophoblast
invasion and embryo-maternal immuno tolerance by killing activated T cells expressing the
Fas membrane protein at the fetal-maternal interface, an effect completely reversed by
antalarmin, a specific CRH-R1 antagonist [19].
We believe that ectopic implantation in the Fallopian tube is manifest by an alteration in
Ucn1 and CRH receptor expression reflecting pathological embryo invasion. We
hypothesised that Ucn1 and CRH receptor mRNA expression in the non-pregnant Fallopian
tube would be similar to that observed in the endometrium but different at tubal implantation
sites and in the decidualized endometrium of women with tubal ectopic compared to
intrauterine pregnancies.
Material and Methods
Tissue collection
Ethical approval for this study was obtained from the Lothian Research Ethics Committee
(LREC 04/S1103/20), and informed written consent was obtained from all study
participants. Timed Fallopian tube biopsies (all full-thickness from ampullary region) were
obtained from health fertile women (age 19-40 years) with regular menstrual cycles (21-35
days) undergoing surgery for benign gynaecological conditions (e.g. heavy menstrual
bleeding, adenomyosis) (n=12) (Table 1). Dating of the samples was ascertained by
consistency of circulating serum estradiol and progesterone levels and histological analysis
of an endometrial biopsy at time of sample collection (using Noyes' criteria). Fallopian tube
was also collected from women undergoing surgery for tubal ectopic pregnancy (n=6).
Decidualized endometrium was obtained from women (age 19-40 years) undergoing
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surgical termination of pregnancy (viable intrauterine) (n = 10, mean gestation 67.4 d);
surgical management of embryonic missed miscarriage (non-viable intrauterine) (n = 7,
mean gestation 71.3 d), and surgical management of tubal ectopic pregnancy (n = 12, mean
gestation 58.1 d). None of the pregnant women had undergone in-vitro fertilization and none
of the women undergoing surgical management of tubal ectopic pregnancy presented acutely
with hemodynamic shock, and all required serial serum β-hCG and ultrasound monitoring
before diagnosis. None of the subjects had received medication (e.g. hormones or
prostaglandins) in the five days leading up to the procedure or had an intra-uterine
contraceptive device in-situ. The decidualized endometrium and trophoblast were obtained
by suction curettage from the women with intrauterine pregnancies and by Pipelle™
(Eurosurgical Ltd., Cranleigh, UK) from the women with tubal ectopic pregnancies. The
decidualized endometrium was isolated from the trophoblast macroscopically. Haematoxylin
and eosin staining and immunohistochemistry for cytokeratin demonstrated clear isolation of
the decidualized endometrium from the trophoblast as described previously [25]. Samples
were either immersed in RNA later (Ambion, Inc., Austin, TX) at 4 °C overnight and flash
frozen at −80 °C for RNA extraction, or immersed in 4% neutral buffered formalin for 24
hours then transferred into 70% ethanol and paraffin embedded for immunohistochemistry.
RNA extraction
Total RNA was extracted from all samples as detailed in the manufacturers' protocol
(Qiagen, West Sussex, UK). The concentration and quality of the extracted RNA was
assessed using an Agilent bioanalyser and quantified using an ND-1000 spectrophotometer
(Nanodrop technologies, DE, USA). All samples were standardized for quality control and
assigned an RNA integrity number (RIN). RNA samples were considered to be of good
quality when a mean RIN value of 7.5 was obtained [26].
Quantitative RT-PCR
After DNAse treatment, using RQ1 DNase (Promega, Southampton, UK), the RNA was
reverse transcribed into cDNA using random hexamers (Applied Biosystems, Foster City,
CA). TaqMan quantitative RT-PCR was then performed using Applied Biosystems'
inventoried TaqMan Gene Expression Assay for the following genes: human urocortin 1
(Ucn1) (Hs00175020_m1), human CRH receptor type 1 (CRH-R1)(Hs01062290_m1) and
human CRH receptor type 2 (CRH-R2) (Hs00266401_m1). All sample reactions were
performed in triplicate and a relative comparison was made to a control tissue cDNA which
was included in all reactions. Using the 2ΔΔCt method, Ucn1, CRH-R1 and CRH-R2
mRNA expression results were normalized against ribosomal 18S internal control (Applied
Biosystems) and expressed as the fold-change when compared with the control group.
Serum assays
Serum progesterone and hCG concentrations were measured using a standard
radioimmunoassay [27]. Levels were correlated to tissue mRNA levels of each gene using
Excel.
Immunohistochemistry
Immunohistochemical localisation of CRH-R1 was performed using a goat polyclonal
antibody (Santa Cruz Biotechnology), biotinylated secondary antibody and peroxidase
conjugated detection. Immunoreactivity was visualised using the chromagen 3,3′-
diaminobenzidine (DAB). Tissue sections were dewaxed in xylene and rehydrated in
descending grades of alcohol. Sections were subjected to antigen retrieval in 0.01M sodium
citrate and non-specific activity was blocked sequentially with 3% hydrogen peroxide
(Sigma-Aldrich), avidin, biotin and protein blocks. Sections were incubated overnight at 4 C
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with primary antibody. Sections were subsequently incubated with biotinylated secondary
antibody (Vector Laboratories, Peterborough, UK) and HRP complex (ABC-Elite, Vector
Laboratories) then immunoreactivity detected using DAB (Vector Laboratories).
Counterstaining was then performed with Harris' haemotoxylin and mounted in Pertex
(Cellpath Technologies, Hemel Hempstead, UK). Negative controls were included where the
primary antibody was pre-incubated with a blocking peptide (Santa Cruz Biotechnology)
and third trimester placenta was used as a positive control.
Scoring
For assessment of CRH-R1 immunostaining in Fallopian tube and endometrium, a
histoscore was applied by two independent observers as previously described [28]. A
separate histoscore was applied to surface epithelium and stroma where appropriate.
Statistical analysis
All data were assessed for normality of distribution using a computer programme (Prism 4;
Graphpad Software, CA, USA). Where the data were normally distributed, and three or
more groups were being analysed, an ANOVA with Tukey's Multiple Comparison Test was
used. Where only two groups were being analysed, a t-test was used. A Chi-squared test was
used to compare proportions. Spearman (non-parametric) coefficients were used to assess
linear correlations. Histoscoring was analysed using the Kruskal-Wallis test assuming a non-
Gaussian distribution. P<0.05 was taken to indicate statistical significance.
Results
Urocortin 1 (Ucn1) mRNA expression in non-pregnant human Fallopian tube and in
Fallopian tube from women with ectopic pregnancy
In the non-pregnant human Fallopian tube, Ucn1 mRNA expression was higher in the
progesterone-dominant luteal phase (mean ΔCT 14.76 ± SEM 0.35, n=8) compared to the
follicular phase (16.44 ± 0.25, n=4) (p<0.01) (Figure 1). In Fallopian tube from women with
ectopic pregnancy (where tubal implantation had occurred), Ucn1 mRNA expression was
similar to that observed in the follicular phase (16.70 ± 0.43, n=6) (Figure 1).
CRH receptor (types 1 and 2) mRNA expression in non-pregnant human Fallopian tube and
in Fallopian tube from women with ectopic pregnancy
Both CRH receptors (types 1 and 2) assumed the same pattern of expression in the non-
pregnant Fallopian tube and in Fallopian tube from women with ectopic pregnancy.
Expression was higher in the follicular (CRH-R1 17.14 ± 0.28; CRH-R2 17.24 ± 0.36; n=4)
compared to the luteal phase (CRH-R1 18.47 ± 0.29; CRH-R2 18.81 ± 0.43; n=8) (p<0.05),
and equivalent to (CRH-R1), or lower than (CRH-R2), the luteal phase in Fallopian tube
from women with ectopic pregnancy (where tubal implantation had occurred) (CRH-R1
19.08 ± 0.23; CRH-R2 19.90 ± 0.29; n=6) (p<0.01) (Figure 2).
Urocortin 1 (Ucn1) mRNA expression in decidualized endometrium from women with
intrauterine and ectopic pregnancy
Ucn1 mRNA expression was lower in the decidualized endometrium from women with
ectopic (18.48 ± 0.19, n=12) compared to viable intrauterine pregnancy (16.63 ± 0.16, n=10)
(p<0.001). No difference in decidual Ucn1 mRNA expression was observed between non-
viable compared to viable intrauterine and ectopic pregnancy (Figure 3). The findings could
not be explained by differences in gestational age.
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CRH receptor (types 1 and 2) mRNA expression in decidualized endometrium from women
with intrauterine and ectopic pregnancy
CRH-R1 mRNA expression was significantly higher in decidualized endometrium from
ectopic (17.36 ± 0.87, n=12) compared to viable intrauterine pregnancy (20.84 ± 0.43, n=10)
(p<0.05). No significant difference in expression was observed when compared to
decidualized endometrium from non-viable intrauterine pregnancy (Figure 4). CRH receptor
type 2 mRNA expression was not significantly different in the decidualized endometrium
from the three groups analysed, but there was a non-significant trend for lower expression in
the non-viable pregnancy group (Figure 4). The findings were correlated with gestation
(days) but could not be explained by differences in gestational age within the study
population.
CRH-R1 protein expression in Fallopian tube and decidualized endometrium
CRH-R1 protein was localised to the epithelium of the Fallopian tube (Figure 5a-c).
Expression was cytoplasmic with nuclear sparing. There was no difference in localization at
different times of the menstrual cycle or in Fallopian tube form women with ectopic
pregnancy. CRH-R1 showed a similar pattern of expression in the decidualized
endometrium although there was evidence of patchy cytoplasmic stromal expression (Figure
5d-f). There was no difference in localisation in the ectopic pregnancy compared to the
intrauterine groups. CRH-R1 protein expression was quantified by applying a histoscore (0–
300) (Figure 6a-c). None of the differences between each group were statistically
significant. However, tubal epithelial CRH-R1 expression showed a non-significant trend
reflecting CRH-R1 expression at the mRNA level. Expression was higher in the follicular
compared to the luteal phase and lower than the luteal phase in Fallopian tube from women
with ectopic pregnancy (where tubal implantation had occurred).
Correlation of decidual urocortin and CRH-R1 mRNA expression with serum progesterone
and hCG concentrations
hCG and progesterone levels were measured in all patients with a viable intrauterine and
ectopic pregnancy. The range of serum hCG concentrations was 22.772-185.815 IU/L for
the women with the viable intrauterine pregnancies and 225-15.956 IU/L for the women
with the ectopic pregnancies. The range of serum progesterone concentrations was
40.99-82.55 nmol/L for the women with the viable intrauterine pregnancies and
20.36-158.13 nmol/L for the women with the ectopic pregnancies. No clear correlation
between decidual Ucn1 or CRH-R1 mRNA expression and serum hCG or progesterone was
observed.
Discussion
To our knowledge, this is the first description of Ucn1 and CRH receptor mRNA expression
in the non-pregnant human Fallopian tube at different stages of the menstrual cycle and in
women with ectopic pregnancy. Furthermore, we also compare the expression of Ucn1 and
CRH receptor mRNA in the decidualized endometrium of women with intrauterine
compared to ectopic pregnancies.
Similar to human endometrium [13], we demonstrate that tubal Ucn1 mRNA expression is
higher in the progesterone-dominant luteal compared to both the follicular phase. We also
show that tubal expression in the luteal phase is higher than that observed in Fallopian tube
from women with ectopic pregnancy where tubal implantation has occurred. The latter data
may be due to the fact that tubal decidualization is not generally observed in ectopic
pregnancy [29,30]. Ucn1 is highly expressed in the secretory endometrium [13] and in EVT
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cells [14], promotes decidualization in-vitro [13], and is only produced in large amounts by
an endometrium receptive to a presenting embryo [16].
In addition, we show that CRH-R1 and CRH-R2 mRNAs are expressed in non-pregnant
Fallopian tube with statistically lower expression in the luteal compared to the follicular
phase. Tubal CRH-R1 protein expression showed a similar non-statistically significant
trend. In the endometrium, the CRH receptors are expressed throughout the menstrual cycle
but cyclical variations have not been reported [18]. Since CRH-R1 promotes implantation
through an inflammatory-like reaction of the endometrium [19], and CRH-R2 promotes
vasodilation within the placental bed [22,23], the reduced expression observed in the
Fallopian tube during the luteal phase may in theory act as a barrier to unwanted ectopic
implantation.
Furthermore, we demonstrate that CRH-R1 and CRH-R2 mRNA expression in Fallopian
tube from women with ectopic pregnancy is also lower than that observed in the follicular
but equivalent to that seen in the luteal phase. We also demonstrate a similar but non-
significant trend in CRH-R1 protein expression. Pregnancies with abnormal placental
function and vascular resistance are characterized by reduced CRH-R1 expression [31].
CRH treatment, mediated by CRH-R1, causes a reduction in the expression of adhesion
molecules and EVT invasion in-vitro [32], and antalarmin, a CRH-R1 specific antagonist,
increases EVT invasion in Matrigel assays allowing an uncontrolled trophoblast invasion
[14]. Moreover, CRH-R2 is expressed in the uterine vascular bed [20,21] and modulates
angiogenesis by inhibiting neovascularization in-vitro [33]. Therefore, we propose that the
low CRH-R1 and CRH-R2 mRNA expression observed at the tubal implantation sites may
contribute to the chaotic trophoblast invasion and aberrant vascularisation associated with
ectopic pregnancy.
We also showed that Ucn1 mRNA expression is lower in decidualized endometrium from
women with an ectopic compared to a normal intrauterine pregnancy. A recent study
showed that Ucn1 levels are directly related to the degree of decidualization of the
endometrium [13] and a direct correlation between Ucn1 concentrations in endometrial
flushings and successful implantation has been reported [16]. Additionally, locally produced
CRH, which shares 45% homology with Ucn1 [7] and acts with lower affinity than Ucn1
through the same receptors [8,9], has been reported to promote implantation and
maintenance of early pregnancy, primarily by inducing apoptosis in activated T cells at the
maternal-fetal interface, allowing controlled trophoblast invasion and implantation into
maternal decidua [19]. Thus, it is likely that a pregnancy implanted in Fallopian tube has
abnormal growth kinetics that are reflected in impaired trophoblast function. Markers of
luteal, trophoblast and decidual function are altered in ectopic pregnancy [34-37]. This study
confirms an alteration in endometrial secretory function in ectopic pregnancy, possibly due
to an absence of trophoblast-derived Ucn1 at the fetal-maternal interface. We are aware that
we have only documented statistically significant changes at an mRNA level and that these
changes may not necessarily be reflected as alterations in protein expression.
We found that CRH-R1 mRNA expression is considerably higher in the decidualized
endometrium of patients with ectopic compared to viable intrauterine pregnancies. CRH-R1
is the only CRH receptor detected in EVT cells and CRH-R1 blockade by antalarmin
prevents implantation in rats by reducing the inflammatory-like reaction of the endometrium
to the invading blastocyst [19]. The maternal endometrial response to the invading semi-
allograft embryo has the characteristics of an acute inflammatory response and, once
implanted, the embryo suppresses this response and prevents its rejection. As CRH-R1 has a
pro-inflammatory effect in a number of tissues [38,39] and is considered necessary for
successful implantation by promoting early embryo-maternal tolerance [19], the increased
Borges et al. Page 6
Reprod Sci. Author manuscript; available in PMC 2011 March 10.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
decidual CRH-R1 mRNA levels observed in ectopic pregnancy may be due to the absence
of intrauterine trophoblast, responsible for the anti-rejection process that protects the fetus
from maternal immune system. Alternatively, as it may be assumed that the genetic make-up
of the EVT cells is similar in intrauterine and ectopic pregnancies, a pro-inflammatory
intrauterine environment leading to abnormal maternal immune tolerance to the fetal semi-
allograft and vice versa may contribute to an environment that is not conducive to normal
intrauterine implantation and lead to ectopic trophoblast invasion.
This finding was not reflected at the protein level possibly reflecting a degree of variation in
the immunohistochemical scoring system and would benefit from quatification by Western
blot analysis on isolated epithelial and stromal epithelial cells.
No correlation was observed between Ucn1 mRNA, or CRH-R1 mRNA, and serum
progesterone or hCG levels in patients, suggesting that other pathways are involved in the
control of Ucn 1/CRH receptor type 1 expression in decidualized endometrium.
In conclusion, this study has demonstrated that: (i) Ucn1 and CRH receptor mRNAs are
expressed in the Fallopian tube across the menstrual cycle, complementing data on their
expression pattern in the endometrium; (ii) Ucn 1 and CRH receptor mRNA expression is
low in the Fallopian tube of women with ectopic pregnancy where tubal implantation has
occurred, attributed to deficient tubal decidualization with ectopic pregnancy; (iii) There is a
likely imbalance between CRH-R1 and its ligand in the decidualized endometrium of
women with ectopic pregnancy, supporting an important role of the CRH family in
endometrial differentiation and embryo implantation. However, further work is required to
quantify these findings at the protein level.
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Figure 1. Urocortin 1 mRNA expression in non-pregnant human Fallopian tube across the
menstrual cycle and in Fallopian tube from women with ectopic pregnancy
* P<0.01 (luteal versus follicular phase). FP = follicular phase; LP = luteal phase; EP =
ectopic pregnancy. Data are mean ± SEM.
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Figure 2. CRH receptor (types 1 and 2) mRNA expression in non-pregnant human Fallopian
tube across the menstrual cycle and in Fallopian tube from women with ectopic pregnancy
CRH receptor mRNA expression was higher in the follicular phase compared to the luteal
phase. CRH receptor mRNA expression was also higher in the follicular phase compared to
Fallopian tube from women with ectopic pregnancy. There was no significant difference in
CRH1 receptor expression in the luteal phase compared to Fallopian tube from women with
ectopic pregnancy. CRH2 receptor expression was significantly lower in ectopic pregnancy
compared to the luteal phase. * P<0.05 (follicular versus luteal) and **P<0.01 (follicular
versus ectopic). EP = ectopic pregnancy. Data are mean ± SEM.
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Figure 3. Decidual expression of Urocortin 1 mRNA
Ucn1 expression is higher in decidualized endometrium from viable intrauterine when
compared to ectopic pregnancies (**p<0.001). No difference in Ucn1 expression was
observed in the decidualized endometrium from non-viable and viable and ectopic
preegnancies. TOP = viable intrauterine pregnancy; Misc = non-viable intrauterine
pregnancy; EP = ectopic pregnancy. Data are mean ± SEM.
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Figure 4. Decidual expression of CRH receptor types 1 and 2 mRNA
CRH receptor type 1 mRNA expression was higher in decidualized endometrium from
patients with ectopic compared to viable intrauterine pregnancy (*p < 0.05). No difference
in CRH receptor type 1 expression was observed between non-viable and ectopic pregnancy.
No difference in CRH receptor mRNA expression was observed in the three groups
analyzed. TOP = termination of pregnancy (viable intrauterine pregnancy); MISC =
miscarriage (non-viable intrauterine pregnancy); Ectopic = ectopic pregnancy. Data are
mean ±SEM.
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Figure 5. CRH-R1 protein immunolocalisation in Fallopian tube and decidualized endometrium
CRH-R1 protein was localised to the epithelium of the Fallopian tube. Expression was
cytoplasmic with nuclear sparing. There was no difference in localisation at different times
of the menstrual cycle or in Fallopian tube form women with ectopic pregnancy. A =
Follicular phase; B = Luteal phase; C = Ectopic pregnancy (all Fallopian tube). CRH-R1
showed a similar pattern of expression in the decidualized endometrium although there was
evidence of patchy cytoplasmic stromal expression. There was no difference in localisation
in the ectopic pregnancy compared to the intrauterine groups. D = Termination of pregnancy
(viable intrauterine); E = Miscarriage (non-viable intrauterine); F = Ectopic pregnancy (all
decidualized endometrium). Insets are negative controls.
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Figure 6. Quantification of CRH-R1 protein expression in Fallopian tube and decidualized
endometrium
CRH-R1 protein expression was quantified (n=5) by applying a histoscore (0-300) and
presented as box and whisker plots (median and range). None of the differences between
each group were statistically significant. However, tubal epithelial CRH-R1 expression
showed a non-significant trend reflecting CRH-R1 expression at the mRNA level. TOP =
viable intrauterine pregnancy; Misc = non-viable intrauterine pregnancy; EP = ectopic
pregnancy.
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Table 1
Demographics for Fallopian tube and endometrial biopsies from women undergoing surgery for benign
gynaecological conditions.
Histological
dating
Serum estrogen
(pmol/l)
Serum
progesterone
(nmol/l)
1 Follicular 1022.87 0.81
2 Follicular 940.44 3.82
3 Follicular 829.42 4.19
4 Follicular 770.63 5.16
5 Follicular 116.3 2.88
6 Weakly
proliferative
55 2.2
7 Mid luteal 242 531
8 Mid luteal 201 24.55
9 Mid luteal 331 83.5
10 Mid luteal 424 76.9
11 Mid luteal 1633 54.38
12 Mid luteal 266 37.1
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